Eviplera emtricitabine/tenofovir/rilpivirine regulatory update

Germany’s Federal Joint Commission (G-BA) issued a final benefit assessment saying HIV drug Eviplera emtricitabine/tenofovir/rilpivirine from Gilead has “no additional benefit” vs. individualized antiretroviral therapy in previously treated HIV patients - an indication the European Commission approved in November. The assessment is in line with an April preliminary assessment from Germany’s Institute for Quality and Efficiency in Healthcare (IQWiG) (see BioCentury, April 7). ...